Other clinical studyOccurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B☆
References (25)
- et al.
Cirrhosis and the aetiology of hepatocellular carcinoma
J Hepatol
(1987) - et al.
Hepatocellular carcinoma and hepatitis B virus
- et al.
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study
J Hepatol
(1994) - et al.
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
Gastroenterology
(1992) - et al.
Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients
Lancet
(1985) - et al.
Hepatocellular carcinoma
- et al.
Hepatocellular carcinoma and cirrhosis: a review of their relative incidence in a 25-year period in the Florence area
Hepatogastroenterology
(1984) - et al.
Changing incidence of hepatocellular carcinoma in Japan
Cancer Res
(1987) - et al.
Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study
Hepatology
(1988) - et al.
A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection
Int J Cancer
(1980)
Hepatitis B virus
Acute and chronic hepatitis revisited
Lancet
(1977)
Cited by (391)
Feasibility of hepatitis B elimination in high-income countries with ongoing immigration
2022, Journal of HepatologyHepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies
2022, Clinical Microbiology and InfectionNatural History of Incidental Enhancing Nodules on Cone-Beam Computed Tomography during Transarterial Therapy of Hepatocellular Carcinoma
2021, Journal of Vascular and Interventional RadiologyCitation Excerpt :The presence of an IEN as a predictor of HCC development at other sites was not statistically significant. The incidence of developing HCC in the setting of liver cirrhosis ranges between 2.5% and 6.6% annually and is independent of treatment efficacy for previous HCC (14–16). It is not uncommon to encounter small enhancing nodules during imaging for locoregional therapy that raises suspicion for de novo HCC arising in the presence of homologous risk factors.
EASL Recognition Awardee 2020: Prof. Giovanna Fattovich
2020, Journal of Hepatology
- ☆
Supported in part by a contract (MR4-0190/NL) from the European Commission.
Copyright © 1995 Published by Elsevier Inc.